Context Therapeutics Inc.
CNTX
$0.52
$0.023.26%
NASDAQ
| 06/30/2026 | 03/31/2026 | 12/31/2025 | 09/30/2025 | 06/30/2025 | |
|---|---|---|---|---|---|
| Revenue | -- | -- | -- | -- | -- |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -- | -- | -- | -- | -- |
| Cost of Revenue | -- | -- | -- | -- | -- |
| Gross Profit | -- | -- | -- | -- | -- |
| SG&A Expenses | 2.44M | 2.33M | 1.96M | 1.89M | 1.93M |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 14.97M | 9.34M | 13.80M | 10.61M | 9.76M |
| Operating Income | -14.97M | -9.34M | -13.80M | -10.61M | -9.76M |
| Income Before Tax | -14.56M | -8.68M | -13.03M | -9.69M | -8.83M |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | -14.56M | -8.68M | -13.03M | -9.69M | -8.83M |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -14.56M | -8.68M | -13.03M | -9.69M | -8.83M |
| EBIT | -14.97M | -9.34M | -13.80M | -10.61M | -9.76M |
| EBITDA | -14.96M | -9.34M | -13.80M | -10.61M | -9.75M |
| EPS Basic | -0.15 | -0.09 | -0.14 | -0.10 | -0.09 |
| Normalized Basic EPS | -0.10 | -0.06 | -0.09 | -0.06 | -0.06 |
| EPS Diluted | -0.15 | -0.09 | -0.14 | -0.10 | -0.09 |
| Normalized Diluted EPS | -0.10 | -0.06 | -0.09 | -0.06 | -0.06 |
| Average Basic Shares Outstanding | 95.18M | 95.18M | 95.18M | 95.19M | 95.19M |
| Average Diluted Shares Outstanding | 95.18M | 95.18M | 95.18M | 95.19M | 95.19M |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |